Half Year 2025 4Dmedical Ltd Earnings Call Transcript
Key Points
- 4DMedical Ltd (ASX:4DX) achieved a 16.5% revenue growth half to half, with a 24% increase in the number of sites and a 37% growth in scan volume.
- The company successfully acquired and integrated Imbio, and secured FDA approval and reimbursement for its IQ-UIP product.
- 4DMedical Ltd (ASX:4DX) has a strategic partnership with Philips, which is expected to significantly boost sales and market reach.
- The company has reduced its operating expenditure by 11% over the last half period, indicating improved financial management.
- 4DMedical Ltd (ASX:4DX) is positioned to replace the $1 billion nuclear VQ market with its superior CT:VQ technology, offering logistical and cost benefits.
- Despite revenue growth, the company is still not profitable and continues to spend more than it earns.
- The Australian revenue has decreased due to the roll-off of a large legacy contract, impacting overall financial performance.
- Engagement with the VA has been challenging due to political changes and cost-cutting measures, affecting potential growth in this segment.
- The company's cash burn rate is high, and recent capital raising efforts only cover one to two quarters of cash needs.
- There is a delay in revenue realization from recent wins, as it takes time for contracts to filter through the system and reflect in financials.
Hi, everyone, welcome to another 4DMedical information webinar. I appreciate your interest and thank you for joining us today.
Think we can skip some of this material and get into the meaty part. So we have our recent momentum's been built on top of a number of key achievements, building success across the VA, the successful acquisition and integration of Imbio, winning reimbursement for both XV LVAS, CT LVAS, expanding across Australia, Qscan, to the North Perth, radiology clinics to the west, and Jones in South Australia. And of course we'll be talking some more today about Philips and the continued progress there with that.
And of course recently, if I focus on our some of our more recent achievements with the FDA approval of IQ-UIP and now reimbursement for IQ-UIP, US DoD Defense Agreement, growing footprint of credible sites, reference sites, and IPOC, CT:VQ and of course, that ties back around to Department of Defense as well.
So our recent revenue momentum has been hard fought
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
